An experimental treatment has shown promise in lowering bad cholesterol, offering hope for people at risk of heart disease but who cannot tolerate drugs known as statins, researchers said Sunday.
Mar 30, 2014
4.4 / 5 (5) | 0
Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable ...
Mar 31, 2014
not rated yet | 0